Fujisawa-Tanaka Chika, Hiratsuka Izumi, Shibata Megumi, Kurihara Kei, Aida Naohiro, Takayanagi Takeshi, Seino Yusuke, Ito Taihei, Kenmochi Takashi, Suzuki Atsushi
Department of Endocrinology, Diabetes and Metabolism, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Department of Transplantation and Regenerative Medicine, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Fujita Med J. 2023 Aug;9(3):194-199. doi: 10.20407/fmj.2022-019. Epub 2022 Dec 27.
Type 1 diabetes mellitus (T1DM) patients with diabetic kidney disease-induced kidney failure have a significantly impaired quality of life (QOL), resulting in a high level of physical, mental, and social anxiety. In this study, we evaluated the QOL of T1DM patients on the list for pancreas transplantation (PTx) at their registration, and determined whether PTx improved their QOL.
There were 58 patients (men/women, 22/36; mean age, 42.8±8.0 years) with T1DM and who were registered on the waiting list for PTx. Quantitative QOL assessment was performed using the Medical Health Survey Short Form (SF-36) version 2. Changes in the QOL before and after PTx were also examined in 24 of these patients.
The mean value of each endpoint and the summary score of the SF-36 physical (PCS), mental (MCS), and role (RCS) components were all below the national normal level at PTx registration. No significant difference in QOL scores was observed in the intergroup comparison of 35 patients on dialysis, 13 patients without dialysis, and ten patients after kidney transplantation. The 24 patients who underwent PTx showed improvement in PCS, MCS, and most SF-36 scores.
T1DM patients waiting for PTx had a decreased QOL, regardless of dialysis, and PTx improved their QOL.
患有糖尿病肾病所致肾衰竭的1型糖尿病（T1DM）患者生活质量（QOL）显著受损，导致身体、心理和社交方面高度焦虑。在本研究中，我们评估了T1DM患者在胰腺移植（PTx）登记时的QOL，并确定PTx是否改善了他们的QOL。
有58例T1DM患者（男/女，22/36；平均年龄，42.8±8.0岁）登记在PTx等待名单上。使用健康调查简表（SF-36）第2版进行定量QOL评估。还对其中24例患者PTx前后的QOL变化进行了检查。
在PTx登记时，SF-36身体（PCS）、心理（MCS）和角色（RCS）分量表的每个终点均值及总分均低于全国正常水平。在35例透析患者、13例未透析患者和10例肾移植后患者的组间比较中，未观察到QOL评分有显著差异。接受PTx的24例患者的PCS、MCS及大多数SF-36评分均有改善。
等待PTx的T1DM患者QOL下降，无论是否透析，且PTx改善了他们的QOL。
